I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Canada

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology ECP 2024
Roche and Genentech at

ECP 2024

September 07 - September 11
Florence, Italy
ecp.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Sep 9 / Roche
Analytic Concordance of a Novel pan-tumor HRD Signature Biomarker Between AVENIO Tumor Tissue CGP Kit V2 (AVENIO CGP) and FoundationOneCDx (F1CDx)
The AVENIO Tumor Tissue CGP Kit V2 (Research Use Only) can measure Homologous Recombination Deficiency through the newly developed HRDsig score. The AVENIO CGP kit showed robust sequencing metrics and high agreement with the reference method (FoundationOne®CDx ) among all variant classes and genomic signatures, including HRDSig HRDsig positive samples were found in various cancer tissue types. HRDsig often correlates with BRCA1/2 mutations. But HRD can also be identified in BRCA wt and/or HRR wt samples, reflecting the ability of HRDSig to capture also non-genomic mechanisms of HRD.
Oncology Cancer ECP-2024

Sign up or login to unlock the full suite of MEDICALLY features
Sep 7 / Roche
Interpretation of B cell malignancies using an ultrasensitive dual in situ hybridization (ISH) for kappa and lambda light chain restriction mRNA demonstrates high level of reproducibility between three sites
Determining clonality in B cell lymphomas with ultrasensitive dual ISH for light chain restriction holds great promise. In this study we determined inter-laboratory reproducibility of a newly developed device across three sites. Interpretation of the assay was highly reproducible across all observations as well as between sites, readers, and days. Pathologists may benefit from this emerging method of determining clonality for potential B cell malignancies in FFPE tissue.
Oncology B Cell Lymphoma ECP-2024

Sign up or login to unlock the full suite of MEDICALLY features
Sep 7 / Roche
Breast Her-2 IHC assessment: pathologists’ concordance is excellent using the binary system (Negative/Positive) but poor using the three-tier system (Negative/Low/Positive). A study of 612 practitioners from 62 countries
Testing of breast cancer tumors into amplified vs non amplified is highly sensitive (97.61%) and specific (98.2%) and well established in clinical routine. This study evaluates clinical relevant error rates for the new 3-tier classification vs the former 2-tier based on data from digital interpretive proficiency tests of 612 practitioners from 62 countries. The 3-tier classification increase potential clinical error rates to 16.6% for infrequently-reporting pathologists, and 12.7% for frequently reporting pathologists. With the lack of a second test this study emphasize the importance of continuous training and proficiency testing.
Oncology Breast Cancer ECP-2024
02:00 PM
Duration 1hr Florence, Italy
Interpretation of B cell malignancies using an ultrasensitive dual in situ hybridization (ISH) for kappa and lambda light chain restriction mRNA demonstrates high level of reproducibility between three sites
Bowdoin Su
Oncology | B Cell Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 1hr Florence, Italy
Analytic Concordance of a Novel pan-tumor HRD Signature Biomarker Between AVENIO Tumor Tissue CGP Kit V2 (AVENIO CGP) and FoundationOneCDx (F1CDx)
Jonathan Choi
Oncology | Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 1hr Florence, Italy
Characterizing Tumor Heterogeneity through Quantitative Pathology Features For Lung Cancer Patients’ Survival Prediction
Paolo Ocampo
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 1hr Florence, Italy
Analytical verification of the Roche HER2 (4B5) Assay to assess HER2-ultralow status in Breast Cancer
Paula Toro
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 1hr Florence, Italy
Analytical performance of a diagnostic immunohistochemical assay for MET protein (c-Met) in non-small cell lung cancer
Landon Inge
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 1hr Florence, Italy
Applicability of a Ki67 image analysis breast algorithm on gastro-intestinal and hepatopancreaticobiliary neuroendocrine neoplasms
Landon Inge
Oncology | Pan-tumour

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 1hr Florence, Italy
Breast Her-2 IHC assessment: pathologists’ concordance is excellent using the binary system (Negative/Positive) but poor using the three-tier system (Negative/Low/Positive). A study of 612 practitioners from 62 countries
Sarah Wedden
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.